IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v566y2019i7745d10.1038_s41586-019-0959-z.html
   My bibliography  Save this article

Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma

Author

Listed:
  • Norbert Hilf

    (Immatics Biotechnologies GmbH)

  • Sabrina Kuttruff-Coqui

    (Immatics Biotechnologies GmbH)

  • Katrin Frenzel

    (BioNTech AG)

  • Valesca Bukur

    (BioNTech AG)

  • Stefan Stevanović

    (Eberhard Karls Universität Tübingen
    German Cancer Consortium (DKTK), German Cancer Research Center Partner Site Tübingen)

  • Cecile Gouttefangeas

    (Eberhard Karls Universität Tübingen
    German Cancer Consortium (DKTK), German Cancer Research Center Partner Site Tübingen
    CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program)

  • Michael Platten

    (University Hospital Heidelberg
    German Cancer Consortium (DKTK), German Cancer Research Center
    Medical Faculty Mannheim)

  • Ghazaleh Tabatabai

    (Eberhard Karls Universität Tübingen
    German Cancer Consortium (DKTK), German Cancer Research Center Partner Site Tübingen
    University Hospital Tübingen)

  • Valerie Dutoit

    (Geneva University Hospital)

  • Sjoerd H. Burg

    (CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program
    Leiden University Medical Center)

  • Per thor Straten

    (CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program
    University Hospital Herlev
    University of Copenhagen)

  • Francisco Martinez-Ricarte

    (Vall d’Hebron University Hospital)

  • Berta Ponsati

    (BCN Peptides SA)

  • Hideho Okada

    (University of California, San Francisco
    Parker Institute for Cancer Immunotherapy)

  • Ulrik Lassen

    (Ringhospitalet)

  • Arie Admon

    (Technion - Israel Institute of Technology)

  • Christian H. Ottensmeier

    (University of Southampton)

  • Alexander Ulges

    (Immatics Biotechnologies GmbH)

  • Sebastian Kreiter

    (BioNTech AG
    CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program)

  • Andreas Deimling

    (University Hospital Heidelberg
    German Cancer Consortium (DKTK), German Cancer Research Center)

  • Marco Skardelly

    (University Hospital Tübingen)

  • Denis Migliorini

    (Geneva University Hospital)

  • Judith R. Kroep

    (Leiden University Medical Center)

  • Manja Idorn

    (University Hospital Herlev
    University of Copenhagen)

  • Jordi Rodon

    (Vall d’Hebron University Hospital
    M. D. Anderson Cancer Center, University of Texas)

  • Jordi Piro

    (BCN Peptides SA)

  • Hans S. Poulsen

    (Ringhospitalet)

  • Bracha Shraibman

    (Technion - Israel Institute of Technology)

  • Katy McCann

    (University of Southampton)

  • Regina Mendrzyk

    (Immatics Biotechnologies GmbH)

  • Martin Lower

    (BioNTech AG)

  • Monika Stieglbauer

    (Eberhard Karls Universität Tübingen
    CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program)

  • Cedrik M. Britten

    (BioNTech AG
    CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program
    Oncology R&D, GlaxoSmithKline)

  • David Capper

    (University Hospital Heidelberg
    German Cancer Consortium (DKTK), German Cancer Research Center
    Charité, University Medicine Berlin)

  • Marij J. P. Welters

    (CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program
    Leiden University Medical Center)

  • Juan Sahuquillo

    (Vall d’Hebron University Hospital)

  • Katharina Kiesel

    (Immatics Biotechnologies GmbH)

  • Evelyna Derhovanessian

    (BioNTech AG)

  • Elisa Rusch

    (Eberhard Karls Universität Tübingen
    CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program)

  • Lukas Bunse

    (University Hospital Heidelberg
    German Cancer Consortium (DKTK), German Cancer Research Center)

  • Colette Song

    (Immatics Biotechnologies GmbH)

  • Sandra Heesch

    (BioNTech AG)

  • Claudia Wagner

    (Immatics Biotechnologies GmbH)

  • Alexandra Kemmer-Bruck

    (BioNTech AG)

  • Jorg Ludwig

    (Immatics Biotechnologies GmbH)

  • John C. Castle

    (BioNTech AG
    Agenus Inc)

  • Oliver Schoor

    (Immatics Biotechnologies GmbH)

  • Arbel D. Tadmor

    (TRON GmbH - Translational Oncology at the University Medical Center of Johannes Gutenberg University)

  • Edward Green

    (German Cancer Consortium (DKTK), German Cancer Research Center
    Medical Faculty Mannheim)

  • Jens Fritsche

    (Immatics Biotechnologies GmbH)

  • Miriam Meyer

    (Immatics Biotechnologies GmbH)

  • Nina Pawlowski

    (Immatics Biotechnologies GmbH)

  • Sonja Dorner

    (Immatics Biotechnologies GmbH)

  • Franziska Hoffgaard

    (Immatics Biotechnologies GmbH)

  • Bernhard Rossler

    (Immatics Biotechnologies GmbH)

  • Dominik Maurer

    (Immatics Biotechnologies GmbH)

  • Toni Weinschenk

    (Immatics Biotechnologies GmbH)

  • Carsten Reinhardt

    (Immatics Biotechnologies GmbH)

  • Christoph Huber

    (BioNTech AG)

  • Hans-Georg Rammensee

    (Eberhard Karls Universität Tübingen
    German Cancer Consortium (DKTK), German Cancer Research Center Partner Site Tübingen)

  • Harpreet Singh-Jasuja

    (Immatics Biotechnologies GmbH)

  • Ugur Sahin

    (BioNTech AG)

  • Pierre-Yves Dietrich

    (Geneva University Hospital)

  • Wolfgang Wick

    (University Hospital Heidelberg
    German Cancer Consortium (DKTK), German Cancer Research Center)

Abstract

The additional author support information was erroneously omitted from the Supplementary Information. This has been corrected online.

Suggested Citation

  • Norbert Hilf & Sabrina Kuttruff-Coqui & Katrin Frenzel & Valesca Bukur & Stefan Stevanović & Cecile Gouttefangeas & Michael Platten & Ghazaleh Tabatabai & Valerie Dutoit & Sjoerd H. Burg & Per thor St, 2019. "Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma," Nature, Nature, vol. 566(7745), pages 13-13, February.
    • Handle: RePEc:nat:nature:v:566:y:2019:i:7745:d:10.1038_s41586-019-0959-z
    DOI: 10.1038/s41586-019-0959-z
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41586-019-0959-z
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/s41586-019-0959-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Jim Middelburg & Marjolein Sluijter & Gaby Schaap & Büşra Göynük & Katy Lloyd & Vitalijs Ovcinnikovs & Gijs G. Zom & Renoud J. Marijnissen & Christianne Groeneveldt & Lisa Griffioen & Gerwin G. W. San, 2024. "T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors," Nature Communications, Nature, vol. 15(1), pages 1-15, December.
    2. Ashish Goyal & Jens Bauer & Joschka Hey & Dimitris N. Papageorgiou & Ekaterina Stepanova & Michael Daskalakis & Jonas Scheid & Marissa Dubbelaar & Boris Klimovich & Dominic Schwarz & Melanie Märklin &, 2023. "DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts," Nature Communications, Nature, vol. 14(1), pages 1-19, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:566:y:2019:i:7745:d:10.1038_s41586-019-0959-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.